Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
315 participants
Mar 11, 2025
INTERVENTIONAL
Conditions
Summary
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care \[(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)\]. The study will run for 52 weeks, inclusive of 26 weeks of TB treatment comprised of 8 weeks of study treatment (experimental or SOC, based on treatment arm assignment) followed by 18 weeks of SOC continuation phase treatment with 45 participants in each experimental treatment arm and at least 90 participants in the SOC arm.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
INH 300 mg will be administered as one tablet orally once daily.
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
PZA will be administered as 500 mg tablets, based on weight, orally once daily.
EMB will be administered as 400 mg tablets, based on weight, orally once daily.
BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
LZD 600 mg will be administered as one 600 mg tablet orally once daily.
TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
Locations(29)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06192160